[1] Pedersen BK. The diseasome of physical inactivity–and the role of myokines in muscle–fat cross talk [J]. J Physiol, 2009, 587(Pt 23): 5559-5568.
[2] IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care [J]. Diabet Med, 2006, 23(6): 579-593.
[3] Pedersen BK. Muscle as a secretory organ [J]. Compr Physiol, 2013, 3(3): 1337-1362.
[4] Hecksteden A, Wegmann M, Steffen A, et al. Irisin and exercise training in humans–results from a randomized controlled training trial [J]. BMC Med, 2013, 3(11): 1-8.
[5] Bostrom P, Wu J, Jedrychowski MP, et al. A PGC-1α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis [J]. Nature, 2012, 481(7382): 463-468.
[6] Aydin S, Kuloglu T. Alterations of irisin concentrations in saliva and serum of obese and normal-weight subjects, before and after 45 min of a Turkish bath or running [J]. Peptides, 2013, 50: 13-18.
[7] Raschke S, Elsen M, Gassenhuber H, et al. Evidence against a beneficial effect of irisin in humans [J]. PLoS One, 2013, 8(9): 1-12.
[8] Hofman T, Elbeh U, Stengel A. Irisin as a muscle-derived hormone stimulating thermogenesis–A critical update [J]. Peptides, 2014, 54: 89-100.
[9] Aydin S, Kuloglu T. Copeptin, adropin and irisin concentrations in breast milk and plasma of healthy women and those with gestational diabetes mellitus [J]. Peptides, 2013, 47: 66-70.
[10] Huh JY, Panagiotou G, Mougios V, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss andexercise [J]. Metabolism, 2012, 61(12): 1725-1738.
[11] Sanchis-Gomar F, Lippi G, Mayero S, et al. Irisin: a new potential hormonal target for the treatment of obesity and type 2 diabetes [J]. J Diabetes, 2012, 4(3): 196.
[12] Choi YK, Kim MK, Bae KH, et al. Serum irisin levels in new-onset type 2 diabetes [J]. Diabetes Res Clin Pract, 2013, 100(1): 96-101.
[13] Stengel A, Hofmann T, Goebel-Stengel M, et al. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity-correlation with body mass index [J]. Peptides, 2013, 39: 125-130.
[14] Castillo-Quan JI. From white to brown fat through the PGC-1 alpha-dependent myokine irisin: implications for diabetes and obesity [J]. Dis Model Mech, 2012, 5(3): 293-295.
[15] Cannon B, Nedergaard J. Nonshivering thermogenesis and its adequate measurement inmetabolic studies [J]. J Exp Biol, 2011, 214(2): 242-253.
[16] Gouveia MC, Vella JP, Cafeo FR, et al. Association between irisin and major chronic diseases: a review [J]. Eur Rev Med Pharmacol Sci, 2016, 20(10): 4072-4077.
[17] Erickson HP. Irisin and FNDC5 in retrospect: an exercise hormone or a transmembrane receptor? [J]. Adipocyte, 2013, 2(4): 289-293.
[18] Staiger H, Bohm A, Scheler M, et al. Common genetic variation in the human FNDC5 locus, encoding the novel muscle-derived 'browning' factor irisin, determines insulin sensitivity [J]. PLoS One, 2013, 8(4): 1-11.
[19] Park KH, Zaichenko L, Brinkoetter M, et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome [J]. J Clin Endocrinol Metab, 2013, 98(12): 4899-4907.
[20] Villarroya F. Irisin, turning up the heat [J]. Cell Metab, 2012, 15(3): 277-278.
[21] Liu JJ, Wong MD, Toy WC, et al. Lower circulating irisin is associated with type 2 diabetes mellitus [J]. J Diabetes Complicat, 2013, 27(4): 365-369.
[22] Yuksel MA, Oncul M, Tuten A, et al. Maternal serum and fetal cord blood irisin levels in gestational diabetes mellitus [J]. Diabetes Res Clin Pract, 2014, 104(1): 171-175.
[23] Crujeiras AB, Pardo M, Arturo RR, et al. Longitudinal variation of circulating irisin after an energy restriction induced weight loss and following weight regain in obese men and women [J]. Am J Hum Biol, 2014, 26(2): 198-207.
[24] Assyov Y, Gateva A, Tsakova A, et al. Irisin in the glucose continuum [J]. Exp Clin Endocrinol Diabetes, 2016, 124(1): 22-27.
[25] Saleem A, Safdar A, Haikalis M, et al. Exercise-induced amelioration of diet-induced obesity and diabetes is not regulated by irisin [J]. FASEB J, 2015, 29(Suppl 1): 992-994.
[26] Yang Z, Chen X, Chen Y, et al. Decreased irisin secretion contributes to muscle insulin resistance in high-fat diet mice [J]. Int J Clin Exp Pathol, 2015, 8(6): 6490-6497.
[27] Bluher S, Panagiotou G, Petroff D, et al. Effects of a 1-year exercise and lifestyle intervention on irisin, adipokines, and inflammatory markers in obese children [J]. Obesity (Silver Spring), 2014, 22(7): 1701-1708.
[28] Polak K, Czyzyk A, Simoncini T, et al. New markers of insulin resistance in polycystic ovary syndrome [J]. J Endocrinol Invest, 2017, 40(1): 1-8.
[29] Jeremic N, Chaturvedi P, Tyagi SC. Browning of white fat: novel insight into factors, mechanisms, and therapeutics [J]. J Cell Physiol, 2017, 232(1): 61-68.
[30] 马晓梅. 鸢尾素与2型糖尿病相关性研究状况 [J]. 中国临床药理学杂志, 2015, 31(21): 2161-2163.
[31] Handschin C, Spiegelman BM. The role of exercise and PGC1alpha in inflammation and chronic disease [J]. Nature, 2008, 454(7203): 463-469.
[32] Aydin S. Three new players in energy regulation: preptin, adropin and irisin [J]. Peptides, 2014, 56(8): 94-110.
[33] Hashemi MS, Ghaedi K, Salamian A, et al. FNDC5 knockdown significantly decreased neural differentiation rate of mouse embryonic stem cells [J]. Neuroscience, 2013, 231(12): 296-304.
[34] Dun SL, Lyu RM, Chen YH. Irisin-immunoreactivity in neural and non-neural cells of the rodent [J]. Neuroscience, 2013, 240(14): 155-162.
[35] Wrann CD, White JP, Salogiannnis J, et al. Exercise induces hippocampal BDNF through a PGC-1alpha/FNDC5 pathway [J]. Cell Metab, 2013, 18(5): 649-659.
[36] Gamas L, Matafome P, Seiça R. Irisin and myonectin regulation in the insulin resistant muscle: implications to adipose tissue: muscle crosstalk [J]. J Diabetes Res, 2015, 2015: 359159.
[37] Chen JQ, Huang YY, Gusdon AM, et al. Irisin: a new molecular?marker?and target?in metabolic?disorder [J]. Lipids Health Dis, 2015, 14(5): 1-6. |
